<p>根据公司在最近向证券交易委员会提交的文件，Private Trust Co. NA 在第三季度将其在史赛克公司（NYSE:SYK - 免费报告）股票中的持仓提高了 157.6%。该机构投资者在此期间购买了 12,188 股后，持有 19,920 股这家医疗技术公司的股票。史赛克占 Private Trust Co. NA 投资组合的 0.6%，使其成为该投资组合中第 20 大持仓。Private Trust Co. NA 在史赛克的持股在最近的报告期末价值为 7,364,000 美元。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他对冲基金最近也买卖了该公司的股票。Mid American Wealth Advisory Group Inc.在第二季度以约 26,000 美元的估值购买了史赛克的新头寸。Elevation Point Wealth Partners LLC 在第二季度以 28,000 美元的估值购买了史赛克的新股份。Sachetta LLC 在第二季度将其在史赛克的持股增加了 58.7%。Sachetta LLC 现在持有 73 股这家医疗技术公司的股票，价值 29,000 美元，此前在上个季度又购买了 27 股。Kilter Group LLC 在第二季度以 29,000 美元的估值购买了史赛克的新头寸。最后，霍华德·休斯医学研究所（Howard Hughes Medical Institute）在第二季度以 29,000 美元的估值购买了史赛克的新头寸。机构投资者持有该公司 77.09% 的股票。</p>
<h2>分析师评级变动</h2>
<p>几位分析师对 SYK 股票发布了报告。富国银行（Wells Fargo &amp; Company）在 11 月 14 日的研究报告中将史赛克的目标股价从 452.00 美元上调至 456.00 美元，并给予该公司 “增持” 评级。Evercore ISI 在 10 月 31 日的报告中将史赛克的目标股价从 410.00 美元下调至 405.00 美元，并为该公司设定了 “跑赢大盘” 评级。Redburn Partners 在 9 月 18 日的研究报告中为史赛克设定了 420.00 美元的目标股价。Truist Financial 在 12 月 18 日的研究报告中将史赛克的目标股价从 400.00 美元下调至 392.00 美元，并为该公司设定了 “持有” 评级。最后，桑福德·C·伯恩斯坦（Sanford C. Bernstein）在 11 月 3 日的研究报告中重新发布了对史赛克的 “跑赢大盘” 评级。十三位分析师对该股票给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat.com 的数据，史赛克目前的共识评级为 “适度买入”，平均目标股价为 431.84 美元。</p>
<ul>
<li>为什么内部人士正在抛售 Robinhood、史赛克和 Mercury Systems 的股票？</li>
</ul>
<p><strong>获取我们最新的史赛克股票分析</strong></p>
<h2>史赛克股票下跌 0.1%</h2>
<p>NYSE:SYK 的股票在周四以 354.54 美元开盘。该股票的 50 日移动平均线为 364.48 美元，200 日移动平均线为 376.90 美元。该公司的市值为 1355.8 亿美元，市盈率为 46.59，市盈增长比率为 2.51，贝塔值为 0.89。该公司的债务与股本比率为 0.68，流动比率为 1.85，速动比率为 1.13。史赛克公司的 1 年最低价为 329.16 美元，1 年最高价为 406.19 美元。</p>
<ul>
<li>当心死亡交叉：3 只股票触发了这个可怕的信号</li>
</ul>
<p>史赛克（NYSE:SYK - 获取免费报告）在 10 月 31 日最后发布了季度收益数据。这家医疗技术公司报告本季度每股收益为 3.19 美元，超出分析师共识预期的 3.13 美元，超出幅度为 0.06 美元。该公司本季度的收入为 60.6 亿美元，而分析师预期为 60.4 亿美元。史赛克的股本回报率为 24.07%，净利润率为 12.07%。该公司的季度收入较去年同期增长了 10.2%。去年同期，该公司每股收益为 2.87 美元。卖方分析师预计史赛克公司今年将发布 13.47 美元的每股收益。</p>
<h2>史赛克增加股息</h2>
<p>该公司最近还披露了季度股息，将于 1 月 30 日（星期五）支付。12 月 31 日的股东将获得 0.88 美元的股息。这相当于每年 3.52 美元的股息，收益率为 1.0%。这比史赛克之前的季度股息 0.84 美元有所增加。除息日期为 12 月 31 日（星期三）。史赛克的股息支付比率（DPR）为 44.15%。</p>
<h2>史赛克的内部活动</h2>
<p>在其他史赛克新闻中，首席财务官普雷斯顿·温德尔·威尔斯（Preston Wendell Wells）在 11 月 20 日（星期四）出售了 165 股公司的股票。股票以平均价格 365.88 美元出售，总价值为 60,370.20 美元。出售后，首席财务官持有该公司 6,694 股股票，价值约为 2,449,200.72 美元。这代表其持股减少了 2.41%。该交易在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，首席会计官威廉·E·贝瑞（William E. Berry, Jr.）在 11 月 14 日（星期五）进行了一笔交易，出售了 1,953 股公司的股票。股票以平均价格 365.49 美元出售，总价值为 713,801.97 美元。交易后，首席会计官直接持有该公司 2,833 股股票，价值约为 1,035,433.17 美元。这笔交易代表其持股减少了 40.81%。该交易的披露可在 SEC 文件中找到。在过去的 90 天里，内部人士已出售 522,118 股公司股票，价值 185,381,932 美元。5.90% 的股票由公司内部人士持有。</p>
<h2>关于史赛克</h2>
<p>（免费报告）</p>
<p>史赛克公司是一家全球医疗技术公司，设计、制造并销售广泛的产品和服务，供医院、外科医生办公室及其他医疗机构使用。其主要业务活动涵盖骨科（包括关节置换植入物、创伤和四肢产品）、外科设备和手术室技术（如可视化、导航和电动仪器）、神经技术和脊柱解决方案，以及病人搬运和紧急医疗设备。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比史赛克更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将爆发</li>
<li>有哪些费用可以从资本利得税中扣除？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI 吧，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在史赛克吗？</h2>
<p>在你考虑投资史赛克之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而史赛克并不在名单上。</p>
<p>虽然史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

史赛克

<p>私人信托公司（Private Trust Co. NA）在第三季度将其在史赛克公司（Stryker Corporation）的持股增加了 157.6%，目前持有 19,920 股，价值 736.4 万美元。史赛克是私人信托公司（Private Trust Co. NA）投资组合中第 20 大持仓。最近，其他几家对冲基金也买卖了史赛克的股票。分析师对史赛克给予了 “适度买入” 的共识评级，平均目标价为 431.84 美元。史赛克的股票开盘价为 354.54 美元，市值为 1355.8 亿美元</p>

<p>Private Trust Co. NA lifted its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 157.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,920 shares of the medical technology company's stock after buying an additional 12,188 shares during the period. Stryker comprises 0.6% of Private Trust Co. NA's investment portfolio, making the stock its 20th largest position. Private Trust Co. NA's holdings in Stryker were worth $7,364,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会提交的文件，Private Trust Co. NA 在第三季度将其在史赛克公司（NYSE:SYK - 免费报告）股票中的持仓提高了 157.6%。该机构投资者在此期间购买了 12,188 股后，持有 19,920 股这家医疗技术公司的股票。史赛克占 Private Trust Co. NA 投资组合的 0.6%，使其成为该投资组合中第 20 大持仓。Private Trust Co. NA 在史赛克的持股在最近的报告期末价值为 7,364,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Other hedge funds also recently bought and sold shares of the company. Mid American Wealth Advisory Group Inc. bought a new position in Stryker during the second quarter valued at approximately $26,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Stryker in the 2nd quarter valued at $28,000. Sachetta LLC grew its holdings in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Kilter Group LLC purchased a new position in Stryker in the 2nd quarter worth $29,000. Finally, Howard Hughes Medical Institute purchased a new position in Stryker in the 2nd quarter worth $29,000. Institutional investors own 77.09% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金最近也买卖了该公司的股票。Mid American Wealth Advisory Group Inc.在第二季度以约 26,000 美元的估值购买了史赛克的新头寸。Elevation Point Wealth Partners LLC 在第二季度以 28,000 美元的估值购买了史赛克的新股份。Sachetta LLC 在第二季度将其在史赛克的持股增加了 58.7%。Sachetta LLC 现在持有 73 股这家医疗技术公司的股票，价值 29,000 美元，此前在上个季度又购买了 27 股。Kilter Group LLC 在第二季度以 29,000 美元的估值购买了史赛克的新头寸。最后，霍华德·休斯医学研究所（Howard Hughes Medical Institute）在第二季度以 29,000 美元的估值购买了史赛克的新头寸。机构投资者持有该公司 77.09% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have issued reports on SYK shares. Wells Fargo &amp; Company upped their price target on shares of Stryker from $452.00 to $456.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, November 14th. Evercore ISI dropped their target price on Stryker from $410.00 to $405.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, October 31st. Redburn Partners set a $420.00 price target on Stryker in a research report on Thursday, September 18th. Truist Financial lowered their price objective on Stryker from $400.00 to $392.00 and set a &#34;hold&#34; rating for the company in a research report on Thursday, December 18th. Finally, Sanford C. Bernstein reissued an &#34;outperform&#34; rating on shares of Stryker in a research note on Monday, November 3rd. Thirteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $431.84.</p>
<div class="lb-trans"><p>几位分析师对 SYK 股票发布了报告。富国银行（Wells Fargo &amp; Company）在 11 月 14 日的研究报告中将史赛克的目标股价从 452.00 美元上调至 456.00 美元，并给予该公司 “增持” 评级。Evercore ISI 在 10 月 31 日的报告中将史赛克的目标股价从 410.00 美元下调至 405.00 美元，并为该公司设定了 “跑赢大盘” 评级。Redburn Partners 在 9 月 18 日的研究报告中为史赛克设定了 420.00 美元的目标股价。Truist Financial 在 12 月 18 日的研究报告中将史赛克的目标股价从 400.00 美元下调至 392.00 美元，并为该公司设定了 “持有” 评级。最后，桑福德·C·伯恩斯坦（Sanford C. Bernstein）在 11 月 3 日的研究报告中重新发布了对史赛克的 “跑赢大盘” 评级。十三位分析师对该股票给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat.com 的数据，史赛克目前的共识评级为 “适度买入”，平均目标股价为 431.84 美元。</p>
</div><ul>
<li>Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么内部人士正在抛售 Robinhood、史赛克和 Mercury Systems 的股票？</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Stryker</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的史赛克股票分析</strong></p>
</div><h2>Stryker Stock Down 0.1%</h2>
<div class="lb-trans"><h2>史赛克股票下跌 0.1%</h2>
</div><p>Shares of NYSE:SYK opened at $354.54 on Thursday. The stock's 50-day moving average is $364.48 and its 200 day moving average is $376.90. The company has a market cap of $135.58 billion, a PE ratio of 46.59, a P/E/G ratio of 2.51 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.</p>
<div class="lb-trans"><p>NYSE:SYK 的股票在周四以 354.54 美元开盘。该股票的 50 日移动平均线为 364.48 美元，200 日移动平均线为 376.90 美元。该公司的市值为 1355.8 亿美元，市盈率为 46.59，市盈增长比率为 2.51，贝塔值为 0.89。该公司的债务与股本比率为 0.68，流动比率为 1.85，速动比率为 1.13。史赛克公司的 1 年最低价为 329.16 美元，1 年最高价为 406.19 美元。</p>
</div><ul>
<li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>当心死亡交叉：3 只股票触发了这个可怕的信号</li>
</ul>
</div><p>Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts' consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The business's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $2.87 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK - 获取免费报告）在 10 月 31 日最后发布了季度收益数据。这家医疗技术公司报告本季度每股收益为 3.19 美元，超出分析师共识预期的 3.13 美元，超出幅度为 0.06 美元。该公司本季度的收入为 60.6 亿美元，而分析师预期为 60.4 亿美元。史赛克的股本回报率为 24.07%，净利润率为 12.07%。该公司的季度收入较去年同期增长了 10.2%。去年同期，该公司每股收益为 2.87 美元。卖方分析师预计史赛克公司今年将发布 13.47 美元的每股收益。</p>
</div><h2>Stryker Increases Dividend</h2>
<div class="lb-trans"><h2>史赛克增加股息</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. This is a boost from Stryker's previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. Stryker's dividend payout ratio (DPR) is 44.15%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 1 月 30 日（星期五）支付。12 月 31 日的股东将获得 0.88 美元的股息。这相当于每年 3.52 美元的股息，收益率为 1.0%。这比史赛克之前的季度股息 0.84 美元有所增加。除息日期为 12 月 31 日（星期三）。史赛克的股息支付比率（DPR）为 44.15%。</p>
</div><h2>Insider Activity at Stryker</h2>
<div class="lb-trans"><h2>史赛克的内部活动</h2>
</div><p>In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the company's stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the sale, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of the firm's stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer directly owned 2,833 shares of the company's stock, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 522,118 shares of company stock worth $185,381,932 over the last ninety days. 5.90% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他史赛克新闻中，首席财务官普雷斯顿·温德尔·威尔斯（Preston Wendell Wells）在 11 月 20 日（星期四）出售了 165 股公司的股票。股票以平均价格 365.88 美元出售，总价值为 60,370.20 美元。出售后，首席财务官持有该公司 6,694 股股票，价值约为 2,449,200.72 美元。这代表其持股减少了 2.41%。该交易在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，首席会计官威廉·E·贝瑞（William E. Berry, Jr.）在 11 月 14 日（星期五）进行了一笔交易，出售了 1,953 股公司的股票。股票以平均价格 365.49 美元出售，总价值为 713,801.97 美元。交易后，首席会计官直接持有该公司 2,833 股股票，价值约为 1,035,433.17 美元。这笔交易代表其持股减少了 40.81%。该交易的披露可在 SEC 文件中找到。在过去的 90 天里，内部人士已出售 522,118 股公司股票，价值 185,381,932 美元。5.90% 的股票由公司内部人士持有。</p>
</div><h2>About Stryker</h2>
<div class="lb-trans"><h2>关于史赛克</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.</p>
<div class="lb-trans"><p>史赛克公司是一家全球医疗技术公司，设计、制造并销售广泛的产品和服务，供医院、外科医生办公室及其他医疗机构使用。其主要业务活动涵盖骨科（包括关节置换植入物、创伤和四肢产品）、外科设备和手术室技术（如可视化、导航和电动仪器）、神经技术和脊柱解决方案，以及病人搬运和紧急医疗设备。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比史赛克更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将爆发</li>
<li>有哪些费用可以从资本利得税中扣除？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI 吧，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在史赛克吗？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资史赛克之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而史赛克并不在名单上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

私人信托公司 NA 增加了在史赛克公司$SYK 的股票持仓